GUARDANT HEALTH CL. A

Guardant Health said at the Morgan Stanley conference it posted more than 40% revenue growth in Q2, an oncology volume increase of over 60% and Shield growth of more than 250%. According to management, Shield covers 80% of eligible individuals (about 94 million people) and cost per test is expected to fall from just over $400 to roughly $350 by year-end, with a long-term target of $200. Guardant360 Liquid CDx received an expanded FDA approval as the sole companion diagnostic for Camizestrant; the company expects ADLT status for Guardant360 in H1 2025 and sees further growth potential from combined screening, profiling and MRD applications despite near-term pricing and reimbursement pressure. » Mere på de.investing.com

Guardant Health announced that EviCore by Evernorth has added the Shield blood test for colorectal cancer early detection to its clinical guidelines effective January 1, 2027. Reimbursement will apply to insured individuals aged 45 and older at average risk, expanding the covered population to about 94 million people across 23 states. Shield is FDA-cleared for primary screening using methylation partitioning cell-free DNA technology; a positive result requires follow-up colonoscopy. The test is included in American Cancer Society and National Comprehensive Cancer Network guidelines and has already been used more than 200,000 times. » Mere på de.investing.com

Guardant Health's FDA-approved and reimbursed Shield blood test provides a painless method for colorectal cancer screening and opens up a mass market. Despite ongoing spending on sales and research, rising test volumes, falling lab costs and partnerships with pharma companies are driving scale-up. The company plans to gradually extend the offering to additional cancer types. » Mere på finanzen.net